West Pharma (WST) Tops Q4 EPS by 10c; misses on guidance

West Pharma (NYSE: WST) reported Q4 EPS of $1.82, $0.10 better than the analyst estimate of $1.72. Revenue for the quarter came in at $748.8 million versus the consensus estimate of $740.75 million.

GUIDANCE:

West Pharma sees FY2025 EPS of $6.00-$6.20, versus the consensus of $7.43. West Pharma sees FY2025 revenue of $2.875-2.905 billion, versus the consensus of $3.04 billion.

For earnings history and earnings-related data on West Pharma (WST) click here.

You May Also Be Interested In

• Apollo Global Management (APO) call put ratio 1 call to 6.8 puts a focus on a spreader of 9K contracts January 95 and 135 puts
• Omnicom launches Acxiom Fan Graph sports marketing platform
• Isoplus selects Navan to manage global travel and expense program